Fifteen start-ups chosen during European Health Catapult French Selection

Experts in innovation, business creation and market entry in life sciences took part during this event

EIT Health France on 4 July 2018 announced the 15 start-ups it has chosen to compete in the European Health Catapult competition. The announcement came at the European Health Catapult French Selection gathering, organised by EIT Health France and held the in the premises of its associate partner, Cap Digital. The European Health Catapult will see start-ups in the MedTech, BioTech and Digital Health sector compete in a final pitch contest to be held at the EIT Health Summit in December.

Each of the French start-ups was invited to present its idea in front of the jury board during a five minute pitch followed by five minutes of questions and answers. The jury was composed of 12 experts, five of which were EIT Health partners (Angels Santé, Inria, Sorbonne University) with strong expertise in supporting start-up in the innovation pathways, business creation and market entry in the life science sector.

After the pitch session, Caroline Sai, operation manager at Angels Santé, introduced the EIT Health Investors Network. This programme aims at connecting European health-oriented investors and promising start-ups to encourage cross-border financing and co-investments. She highlighted the possibilities which the programme offers each of the involved parties.

At the end of the day, ten European BioTech teams, previously selected in EIT Health BioEntrepreneur Bootcamp 2018, had the opportunity to pitch their idea in front of the jury and public. This event was part of their three-day trip to Paris, organised by the French partner Medicen, where they had the opportunity to meet local French life sciences ecosystems, initiate collaborations and challenge their business models and value propositions.

The event ended with a social networking cocktail where start-ups were able to meet jury members and experts. With more than 70 people attending the regional selection, this event was a remarkable success for the EIT Health France team.

The pre-selected start-ups:

Medtech:

• Lifeina – The world’s smallest connected fridge for the safe transport and storage of medication, and for better adherence to medication.
• Neurallys – Innovating in neuroscience by means of connected medical devices, improving the patient comfort of life and helping physicians’ follow-up.
• EzyGain – Developed a patented connected device for rehabilitation of walking abilities that can be used in health centres or at home.
• Cartimage Medical SAS – Surgical imaging devices to optimise joint preservation and osteo-arthritis prevention.
• Aenitis – Develop innovative med-devices for continuous, contactless and pressureless sorting of cells in suspensions, using acoustic Radiation Forces.
• VitaDX – Developing a solution for early bladder cancer diagnosis using fluorescence imaging, image processing and machine learning algorithm.
• AP Advance SAS – Develops a light, wearable and affordable patch-artificial pancreas to restore insouciance in all insulin-requiring diabetic patients.

Digital Health:

• Medicapp Connect – Brings health professionals a unique multichannel software that improves their productivity and facilitates communications.
• INVIVOX / IN SITU TRAINING – A global solution for on-site, Peer-to-Peer medical training.
• CO-ASSIST – Develops an alert watch to secure elder people at home and beyond.
• Wefight – The vision is to never leave a patient alone. Our solution is Vik a virtual companion that addresses any concerns of patients with chronic disease.
• DeepOR – Develops a smart assistant powered by Natural Language Processing to optimise hospital workflows and increase patient safety.
• FeetMe SAS – A digital health company developing innovative connected technologies and services to improve patient outcomes in functional care.

Biotech:

• Smart Immune – A French clinical-stage biopharmaceutical company focused, on developing new cell and gene therapy to treat T-cell immunodeficiency.
• ONCAMINE Pharmaceuticals – We want to reposition a deprioritised clinical stage oncology drug and take it to the market for the treatment of patients with acute myeloid leukemia.

Click here to learn more about the European Health Catapult programme.

Learn more about Cap Digital here.

For any further enquiries contact:

Albane Pariset, albane.pariset@eithealth.eu